Clinical Trials Logo

Metastatic clinical trials

View clinical trials related to Metastatic.

Filter by:

NCT ID: NCT01974752 Completed - Uveal Melanoma Clinical Trials

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

SUMIT
Start date: April 2014
Phase: Phase 3
Study type: Interventional

Selumetinib therapy in patients with metastatic uveal melanoma.

NCT ID: NCT01745757 Completed - Breast Cancer Clinical Trials

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer

COMET
Start date: June 2012
Phase:
Study type: Observational

Bevacizumab plus chemotherapy improves response rates and prolongs PFS when used as first- and second-line therapy for advanced breast cancer. However, bevacizumab has not improved OS in the individual studies currently reported. In Europe, EMA has maintained its indication associated with weekly paclitaxel in first line metastatic breast cancer and more recently with capecitabine based on RIBBON 1 trial's results. The identification of patient subsets that receive the most clinical benefit would enable more specific treatment administration of bevacizumab and allow patients unlikely to benefit the opportunity to seek other treatment modalities. Unfortunately, despite efforts to identify patient subsets with a differential benefit from bevacizumab, no validated biomarkers have been defined. The Avastin cohort is a unique opportunity to investigate various biological and imaging parameters which could be related to clinical benefit of the combination of bevacizumab and weekly paclitaxel in first line metastatic breast cancer in a homogeneously treated population in French cancer centers. This trial will gather the expertise of several translational research platforms of different cancer centers from the UNICANCER consortium.

NCT ID: NCT01719744 Completed - Soft Tissue Sarcoma Clinical Trials

Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.

NCT ID: NCT01703585 Completed - Breast Cancer Clinical Trials

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

Start date: October 4, 2012
Phase:
Study type: Observational

This is a feasibility study to look for genetic alterations in tissue and blood samples that may be useful in determining what treatments may be useful in the patient's cancer care.

NCT ID: NCT01633645 Completed - Clinical trials for Non Small Cell Lung Cancer

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to establish the objective response rate (complete response + partial response) following treatment with VELCADE in combination with cisplatin plus gemcitabine in patients with locally advanced (Stage IIIb) or metastatic (stage IV non-small cell lung cancer (NSCLC) who have not received prior antineoplastic therapy for advanced disease

NCT ID: NCT01216345 Completed - Locally Advanced Clinical Trials

Cetuximab + Gemox in Biliary Tract Cancer

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.

NCT ID: NCT00509964 Recruiting - Stomach Neoplasm Clinical Trials

Second-Line Irinotecan vs. ILF for AGC

Start date: May 2007
Phase: Phase 2
Study type: Interventional

Patients with recurrent or metastatic gastric cancer can benefit from palliative chemotherapy. However, over half of patients with metastatic gastric cancer who received chemotherapy failed to achieve response and even in these responders, the duration of responses was as short as a few months. Patients with metastatic gastric cancer who fail to respond or have relapse after first line chemotherapy have a grim prognosis and a standard salvage treatment is not available. We designed this phase II trial to determine the efficacy and safety of irinotecan monotherapy or combination (ILF) as second-line therapy for advanced gastric cancer.

NCT ID: NCT00507091 Completed - Adenocarcinoma Clinical Trials

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Start date: August 2005
Phase: Phase 1
Study type: Interventional

A Phase I open label study to asses the safety and tolerability of ZD6474 in combination with Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma.

NCT ID: NCT00498797 Completed - Prostate Cancer Clinical Trials

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.